Antitumor efficacy of doxorubicin encapsulated in neovasculature targeting liposomes

Abstract

Abstract: It was reported that a 5-amino acid peptide Ala-Pro-Arg-Pro-Gly (APRPG) could specifically bind to the tumor angiogenic site. We investigated the antitumor efficacy of doxorubicin (DOX) encapsulated in APRPG modified liposome (APRPG-LP) compared with DOX encapsulated in non-APRPG modified liposomes (LP) and DOX solution (free DOX) on Lewis lung carcinoma (LLC) bearing mice. APRPG-LP could efficiently suppress the tumor growth of the experimental mice, compared with LP (P<0.001), free DOX (P<0.001) and saline of negative control (P<0.001). The present results demonstrated that the APRPG modified liposomes exhibited a much better therapeutic efficacy over the non-modified liposomes and the DOX solution, because of the effect of targeted tumor angiogenesis disruption. Thus, APRPG-LP could be a promising active-targeting drug carrier to tumor angiogenic site.

Key words: Liposomes, Liposomes, Doxorubicin, Doxorubicin, Antitumor efficacy, Antitumor efficacy, Angiogenesis, Angiogenesis, Active targeting, Active targeting

CLC Number:

R943.42

Supporting:

Song Zhuang, Xian-Rong Qi^*. Antitumor efficacy of doxorubicin encapsulated in neovasculature targeting liposomes [J]. .

References

[1] Folkman, J. Nat. Med. 1995, 1, 27-30.
[2] Kumar, S.; Li, C. Trends Immunol. 2001, 22, 129.
[3] Niethammer, A.G.; Xiang, R.; Becker, J.C.; Wodrich, H.; Pertl, U.; Karsten, G.; Eliceiri, B.P.; Reisfeld, R.A. Nat. Med. 2002, 8, 1369-1375.
[4] Sebastian, S.; Martin, E.; Birgitta, S.; Brita, S.; Michael, T.; Uwe, M.; Marc, D. Int. J. Cancer. 2004, 110, 117-124.
[5] Joanna, K.; Tyler, W.; Michael, T.; Russell, M. J. Controlled Release. 2006, 12, 312-319.
[6] Oku, N.; Asai, T.; Watanabe, K.; Kuromi, K.; Nagatsuka, M.; Kurohane, K.; Kikkawa, H.; Ogino, K.; Tanaka, M.; Ishikawa, D.; Tsukada, H.; Momose, M.; Nakayama, J.; Taki, T. Oncogene. 2002, 21, 2662-2669.
[7] Asai, T.; Shimizu, K.; Kondo, M.; Kuromi, K.; Watanabe, K.; Ogino, K.; Taki, T.; Shuto, S.; Matsuda, A.; Oku, N. FEBS Lett. 2002, 520, 167-170.
[8] Asai, T.; Miyazawa, S.; Maeda, N.; Hatanaka, K.; Katanasaka, Y.; Shimizu, K.; Shuto, S.; Oku, N. Cancer Sci. 2008, 99, 1029-1033.
[9] Katanasaka, Y.; Ida, T.; Asai, T.; Shimizu, K.; Koizumi, F.; Maeda, N.; Baba, K.; Oku, N. Cancer Lett. 2008, 270, 260-268.
[10] Maeda, N.; Takeuchi, Y.; Takada, M.; Namba, Y.; Oku, N. Bioorg. Med. Chem. Lett. 2004, 14, 1015-1017.
[11] Kim, W.J.; Yockman, J.W.; Jeong, J.H. J. Controlled Release. 2006, 114, 381-388.
[12] Suh, W.; Han, S.O.; Yu, L.; Kim, S.W. Mol. Ther. 2002, 6, 664-672.
[13] Fritze, A.; Hens, F.; Kimpfler, A.; Schubert, R.; Peschka-Süss, R. Biochim. Biophys. Acta. 2006, 1758, 1633-1640.
[14] Liu, H.Y.; Wu, J.; Yuan, S.J. Methodology of New Drug Research in Pharmacology. Beijing: Chemical Industry Press, 2007, 253-254.
[15] Osheroff, N.; Corbett, A.H.; Robinson, M.J. Adv. Pharmacol. 1994, 29B, 105-126.
[16] Uchiyama, K.; Nagayasu, A.; Yamagiwa, Y.; Nishida, T.; Harashima, H.; Kiwada, H. Int. J. Pharm. 1995, 121, 195-203.
[17] Nagayasu, A.; Uchiyama, K.; Kiwada, H. Adv. Drug Deliv. Rev. 1999, 40, 75-87.
[18] Zou, Y.; Ling, Y.H.; Reddy, S.; Priebe, W.; Perez-Soler, R. J. Cancer. 1995, 61, 66-671.
[19] Samad, A.; Sultana, Y.; Aqil, M. Curr. Drug Deliv. 2007, 4, 297-305.
[20] Matsumura, Y.; Maeda, H. Cancer Res. 1986, 46, 6387-6392.